Significant Ownership of UBS Group AG

Notable people
Europe Se Ubs, Ubs la Maison de Gestion
Large-stake snapshot 1 signal
Large-stake filing summary
  • Recent SEC Schedule 13D/G filings for UBS Group AG focus on large-stake beneficial ownership disclosures and amendments.
  • Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
Manager Names, identifiers, and filing context for this profile. 2 identity fields
Manager signature
Andrew Johnson - Director
Manager location
Zurich

Follow Filing Activity

Follow UBS Group AG with Pro and return when a new Schedule 13D/G filing changes the record on this page.

Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.

Review Pro alert access Already have an account? Sign in and return here

Significant Ownership of UBS Group AG

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ACPPRA abrdn Income Credit Strategies Fund 5.250% Series A Perpetual Preferred Shares 30% $9,445,804 -$1,529,312 480,458 -14% UBS Group AG 30 Jun 2026
Vipshop Holdings Ltd Class A ordinary shares, par value US$0.0001 per share 20% 16,129,947 +1.2% UBS Group AG 31 Mar 2026
INN Summit Hotel Properties, Inc. Common stock 8.1% $57,626,725 8,757,861 UBS Group AG 30 Jun 2026
NCA NUVEEN CALIFORNIA MUNICIPAL VALUE FUND Common Shares 6.6% $20,489,190 +$3,563,317 2,170,465 +21% UBS Group AG 30 Jun 2026
IHS IHS Holding Ltd Ordinary Shares, par value USD 0.30 per share 5.8% $159,806,865 19,394,037 UBS Group AG 30 Jun 2026
RVPH REVIVA PHARMACEUTICALS HOLDINGS, INC. Common Stock, par value $0.0001 per share 5.8% $133,178 746,095 UBS Group AG 31 Mar 2026
TBLD Thornburg Income Builder Opportunities Trust Common Shares 5.6% $32,123,078 1,803,654 UBS Group AG 30 Sep 2024
FOLD AMICUS THERAPEUTICS, INC. Common Stock, par value $0.01 per share 5.5% $247,870,674 17,141,817 UBS Group AG 31 Mar 2026
RDAC Rising Dragon Acquisition Corp. Common stock 5.5% $1,668,588 324,628 UBS Group AG 30 Jun 2026
OTAIU Starlink AI Acquisition Corp Units, each consisting of one ordinary share and one right to receive one-fourth (1/4) of one ordinary share 5.4% $7,495,560 740,668 UBS Group AG 30 Jun 2026
APEX Tech Acquisition Inc. Units, each consisting of one ordinary share and one right 5.4% 762,688 UBS Group AG 31 Mar 2026
ADD Color Star Technology Co., Ltd. Class A Ordinary Shares, par value $0.04 0% $0 -$26,013 0 -100% UBS Group AG 31 Mar 2025
AMC AMC ENTERTAINMENT HOLDINGS, INC. Class A common stock 0% $0 0 UBS Group AG 30 Jun 2026
AMRX Amneal Pharmaceuticals, Inc. Class A Common Stock, par value $0.01 per share 0% $0 -$160,759,270 0 -100% UBS Group AG 31 Dec 2024
RVPH REVIVA PHARMACEUTICALS HOLDINGS, INC. Common Stock, par value $0.0001 per share 0% $0 0 UBS Group AG 30 Jun 2026
INFN Infinera Corp Common stock, par value $0.001 per share 0% $0 -$1,025,831,283 0 -100% UBS Group AG 31 Mar 2025
IGI Western Asset Investment Grade Opportunity Trust Inc. Common Stock 0% $0 -$5,592,253 0 -100% UBS Group AG 31 Mar 2026
PAXS PIMCO Access Income Fund Common Stock 0% $0 -$34,269,330 0 -100% UBS Group AG 31 Mar 2025
CLX CLOROX CO /DE/ Common Stock, $1.00 Par Value Per Share 0% $0 -$1,387,317,511 0 -100% UBS Group AG 31 Mar 2025
RPD Rapid7, Inc. Common Stock, par value $0.01 per share 0% $0 -$77,373,736 0 -100% UBS Group AG 30 Jun 2025
LBRDK Liberty Broadband Corp Series C common Stock 0% $0 -$670,969,858 0 -100% UBS Group AG 31 Dec 2024
LDP Cohen & Steers Ltd Duration Preferred & Income Fund, Inc. Common Stock, $0.01 par value 0% $0 0 UBS Group AG 30 Sep 2024
RNLXY Renalytix plc Ordinary shares, nominal value 0.0025 per share 0% 0 UBS Group AG 31 Mar 2025

Schedules 13D/G Reported by UBS Group AG:

Sym Target Class Ownership Change Current shares Change Value Reporting name Form Report period Filing date
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .